Affordable Access

Publisher Website

The coagulation biology of cancer

Authors
Journal
Fibrinolysis and Proteolysis
0268-9499
Publisher
Elsevier
Publication Date
Volume
6
Identifiers
DOI: 10.1016/0268-9499(92)90092-v
Disciplines
  • Medicine

Abstract

Abstract It is common knowledge that blood coagulation and fibrinolysis are activated systemically in patients with malignancy. Studies in specific in vitro and animal models of malignancy have implicated either tumour cell procoagulants or urokinase in promoting malignant disease progression, based on the participation of one or the other of these in mechanisms of tumour cell proliferation, invasion, and metastasis. It has recently been shown that individual human tumour types may manifest either a tumour cell-associated coagulation pathway in the absence urokinase, urokinase expression in the absence of a tumour cell-associated coagulation pathway, or neither of these. Mounting evidence suggests that anticoagulant and urokinase therapy are capable of ameliorating the clinical course of a procoagulant tumour type namely, small cell carcinoma of the lung. Clinical trials of agents capable of inhibiting urokinase-initiated proteolysis are required to clarify cause/effect relationships in urokinase-expressing tumours.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

[Coagulation and bronchopulmonary cancers: from cl...

on Revue des maladies respiratoir... 1992

Systems biology of coagulation.

on Journal of thrombosis and haem... June 2013

Cancer biology.

on Current Opinion in Oncology January 1996

Cancer biology.

on Current Opinion in Oncology January 1999
More articles like this..